Status:
COMPLETED
Home OCT Repeatability and Reproducibility of Automatic Fluid Quantification Study
Lead Sponsor:
Notal Vision Inc.
Conditions:
Neovascular Age-related Macular Degeneration
Eligibility:
All Genders
18+ years
Brief Summary
The study will enroll up to 30 AMD patients diagnosed with NV-AMD in at least one eye at the time of enrollment. At the Study Visit, fluid must be present in at least one eye of the subjects. If only ...
Detailed Description
Description of Study Procedures and In-Office Visit: Enrollment/Screening: At the Enrollment/ Screening Visit, the exams will be conducted in the following order: 1. Patient will be informed concer...
Eligibility Criteria
Inclusion
- Ability to speak, read and understand English.
- Ability to understand and agree to contents of informed consent in writing or verbal.
- Adult diagnosed with NV-AMD in at least one eye based on the subject's medical record.
- Fluid presence in the study eye per the PI review of Screening commercial OCT.
- Best corrected Visual Acuity of 20/320 or better in the study eye.
- Available and willing to conduct self-scanning in the office
Exclusion
- Any other retinal disease requiring steroidal or anti-VEGF injections.
- Dilated pupils
Key Trial Info
Start Date :
September 13 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 5 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05281042
Start Date
September 13 2021
End Date
January 5 2022
Last Update
April 5 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Elman Retina Group
Glen Burnie, Maryland, United States, 21061